Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation

Bone Marrow Transplantation

Volumn 25, Issue 3, 2000, Pages 237-241

  Holler, E ^a,b,e   Roncarolo, M G ^c,d   Hintermeier Knabe, R ^a   Eissner, G ^b   Ertl, B ^a   Schulz, U ^b   Knabe, H ^b   Kolb, H J ^a,b   Andreesen, R ^f   Wilmanns, W ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c MERCK RESEARCH LABORATORIES   (United States)

^d SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^e UNIVERSITY OF REGENSBURG   (Germany)

^f NONE

Author keywords

Bone marrow transplantation; GVHD; IL 10; TNF

Indexed keywords

INTERLEUKIN 10;

ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; T LYMPHOCYTE;

EID: 0033953163     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702126     Document Type: Article

References (29)

1. Xun CQ, Thompson JS, Jennings CD et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994; 83: 2360-2367.
2. Cooke KR, Kobzik L, Martin TR et al. An experimental model of idiopathic syndrome after bone marrow transplantation: I. The role of minor H antigens and endotoxin. Blood 1996; 88: 3230-3239.
3. Holler E, Kolb HJ, Mittermueller J et al. Modulation of acute graft-versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor alpha (TNFa) release in the course of pretransplant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNFa (MAK195F). Blood 1995; 86: 890-899.
4. Antin JH, Ferrara JLM. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80: 2964-2968.
5. Antin JH, Weinstein HJ, Guinan EC et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid resistant graft-versus-host disease. Blood 1994; 84: 1342-1348.
6. Herve P, Flesch M, Tiberghien P et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992; 79: 3362-3368.
7. de Waal Malefyt R, Yssel H, Roncarolo MG et al. Interleukin 10. Current Opin Immunol 1992; 4: 314-320.
8. Willems F, Marchant A, Delville JP. Interleukin 10 inhibits B7 and intercellular adhesion molecule-1 expression on human monocytes. Eur J Immunol 1994; 24: 1007-1009.
9. Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a long term antigen specific anergic state in human CD4+ T cells. J Exp Med 1996; 184: 19-29.
10. Bacchetta R, Bigler M, Touraine JL et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA-mismatched hematopoietic stem cells. J Exp Med 1994; 179: 493-502.
11. Blazar BR, Taylor PA, Smith S, Vallera DA. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 1995; 85: 842.
12. Krenger W, Snyder K, Smith S, Ferrara JLM. Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens. Transplantation 1994; 58: 1251-1257.
13. Hempel L, Korholz D, Nusshaum P et al. High interleukin-10 serum levels are associated with fatal outcome in patients after bone marrow transplantation. Bone Marrow Transplant 1997; 20: 365-368.
14. Remberger M, Ringden O. Serum levels of cytokines after bone marrow transplantation: increased IL-8 levels during severe veno-occlusive disease of the liver. Eur J Haematol 1997; 59: 254-262.
15. Holler E, Kolb HJ, Möller A et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation. Blood 1990; 75: 1011-1016.
16. Holler E, Kolb HJ, Hintermeier-Knabe R et al. Role of tumor necrosis factor alpha in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc 1993; 25: 1234-1236.
17. Eissner G, Lindner H, Behrends U et al. Influence of bacterial endotoxin on radiation-induced activation of human endothelial cells in vitro and in vivo: protective role of IL-10. Transplantation 1496; 62: 819-827.
18. Lindner H, Holler E, Gerbitz A et al. Influence of bacterial endotoxin on radiation-induced activation of human endothelial cells in vitro and in vivo: 2. IL-10 protects against trans-endothelial migration. Transplantation 1997; 64: 1370-1373.
19. Steinbrink K, Wölff M, Jonuleit H et al. Induction of tolerance by IL-10 treated dendritic cells. J Immunol 1997; 159: 4772-4780.
20. Cortes JE, Talpaz M, Cabanillas F et al. Serum levels of interleukin 10 in patients with diffuse large cell lymphoma: lack of correlation with prognosis. Blood 1995; 85: 2516-2520.
21. Pawelec G, Rehbem A, Schlotz E, da Silva P. Cellular immune responses to autologous chronic myelogenous leukemia cells in vitro. Cancer Immunol Immunother 1996; 42: 193-199.
22. Wanidworanum C, Strober W. Predominant role of tumor necrosis factor alpha in human monocyte IL-10 synthesis. J Immunol 1993; 151: 6853-6861.
23. Holler E, Hintermeier-Knabe R, Kolb HJ et al. Low incidence of transplant related complications in patients with chronic release of TNF alpha before admission in bone marrow transplantation - a clinical correlate of cytokine desensitization? Pathobiol 1991; 59: 171-175.
24. Barsig J, Küsters S, Vogt K et al. Lipopolysaccharide-induced interleukin-10 in mice: role of endogenous tumor necrosis factor-α. Eur J Immunol 1995; 25: 2888-2893.
25. Middleton PG, Taylor PR, Jackson G et al. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood 1998; 92: 3943-3948.
26. Mayer F, Messer G, Knak W et al. High response of TNF-α secretion in vivo in patients undergoing BMT may be associated with the -308 bp TNF-α gene enhancer polymorphism. Bone Marrow Transplant 1996; 17: S101.
27. + T-cell subset inhibits antigen specific T-cell responses and prevents colitis. Nature 1997; 389: 737-742.
28. Howard M, Muchamuel T, Andrade S, Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993; 177: 1205-1208.
29. Greenberger MJ, Stricter RM, Kunkel SL et al. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 1995; 155: 722-729.